Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heteroclitic immunization induces tumor immunity

R Dyall1, W B Bowne, L W Weber

  • 1T Cell Development Laboratory, Immunology Program, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.

The Journal of Experimental Medicine
|November 6, 1998
PubMed
Summary

Designing heteroclitic CTL vaccines enhances anti-tumor immunity. This approach effectively targets poorly immunogenic tumor peptides, demonstrating in vivo applicability for cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Profile and immune environment of upper tract urothelial carcinoma].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Cytometry-based analysis of HLA-G functions according to ILT2 expression.

Human immunology·2020
Same author

Experimental evidence on promotion of electric and improved biomass cookstoves.

Proceedings of the National Academy of Sciences of the United States of America·2019
Same author

Black patients sustain vision loss while White and South Asian patients gain vision following delamination or segmentation surgery for tractional complications associated with proliferative diabetic retinopathy.

Eye (London, England)·2017
Same author

The role of methylation, DNA polymorphisms and microRNAs on HLA-G expression in human embryonic stem cells.

Stem cell research·2017
Same author

Frequency of HIV-testing and factors associated with multiple lifetime HIV-testing among a rural population of Zambian men.

BMC public health·2015

Area of Science:

  • Immunology
  • Cancer Research
  • Vaccinology

Background:

  • Cytotoxic T lymphocytes (CTLs) are key in anti-tumor immunity, recognizing tumor-associated peptides presented by MHC class I molecules.
  • Many tumor peptides are poor immunogens, hindering effective CTL activation and tumor rejection.
  • Understanding MHC class I:peptide:TCR interactions is crucial for designing potent anti-cancer vaccines.

Purpose of the Study:

  • To design and evaluate heteroclitic CTL vaccines targeting poorly immunogenic tumor peptides.
  • To demonstrate the in vivo efficacy of heteroclitic immunization against tumors using viral and self-antigens.
  • To establish the applicability of heteroclitic immunization for overcoming immune tolerance to tumor-associated antigens.

Main Methods:

  • Utilized MHC binding motifs and structural knowledge of class I:peptide:TCR complexes to design heteroclitic CTL vaccines.

Related Experiment Videos

  • Employed a synthetic variant of a viral antigen as a model tumor antigen for heteroclitic peptide and DNA immunization.
  • Developed a heteroclitic peptide vaccine targeting a tyrosinase family self-antigen expressed by melanoma cells.

    • Main Results:

    • Heteroclitic immunization with peptides and DNA conferred protection against tumor challenge and induced regression of established tumors in a viral antigen model.
    • The designed heteroclitic peptide vaccine successfully induced tumor protection against melanoma cells expressing a self-antigen.
    • Demonstrated in vivo potency of heteroclitic immunization in overcoming immune tolerance to poorly immunogenic tumor peptides.

    Conclusions:

    • Heteroclitic immunization is a viable strategy for enhancing anti-tumor CTL responses.
    • This approach can effectively target and overcome immune evasion mechanisms employed by tumors, including those involving self-antigens.
    • The findings support the in vivo applicability of heteroclitic immunization for developing novel cancer immunotherapies.